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Somatostatin-receptor scintigraphy in primary breast cancer
Summary
Somatostatin-receptor (SS-R) scintigraphy successfully
shows primary cancers and distant metastases in most
patients with carcinoids, islet cells tumours, and
paragangliomas. Previous in-vitro studies indicated that
somatostatin receptors are present in human breast cancers.
We report positive scintigraphy with [111In-DTPA-D-Phe1]-
octreotide in 39 of 52 primary breast cancers (75%). Parallel
in-vitro autoradiography with [125I-Tyr3]-octreotide of 30 of
these showed a corresponding somatostatin-receptor status
in 28. Significantly more invasive ductal cancers could be
shown than invasive lobular carcinomas (85% vs 56%;
p<0&middot;05). Also the number of T2 cancers which were shown
was higher than T1 (86% vs 61%; p<0&middot;05). Imaging of the
axillae showed non-palpable cancer-containing lymphnodes in
4 of 13 patients with subsequently histologically-proven
metastases. In the follow-up after a mean of 2&middot;5 yr, SS-R
scintigraphy in 28 of the 37 patients with an originally SS-R-
positive cancer, was positive in the 2 patients with clinically-
recognised metastases, as well as in 6 of the remaining 26
patients who were symptom-free. Raised carcinoembryonic
antigent (CEA) and CA 15-3 values were observed in only 2
and 1, respectively, of these patients.
Most primary breast cancers can be shown by SS-R
scintigraphy, especially invasive ductal cancers. This
technique may be of value in selecting patients for clinical
trials with somatostatin analogues or other medical
treatments. Furthermore, SS-R scintigraphy is more sensitive
than measurements of the usual serum cancer markers for
detecting recurrences of SS-R-positive breast cancer.
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Introduction
Somatostatin receptors (SS-R) have been found in
neuroendocrine tumours (carcinoids, islet cell tumours,
paragangliomas) as well as in meningiomas.1-5 Studies also
show SS-Rs in some primary breast cancers,6-9 probably of
neuroendocrine origin.8 Antiproliferative effects of
somatostatin analogues have been reported on the growth of
experimental cancers, including breast-cancer cell lines and
explants.lO.l1 We recently introduced a new technique in
which SS-R-positive cancers could be shown in vivo, after
giving radionuclide-labelled somatostatin analogue
followed by gamma-camera scintigraphy.12-16 In the
present study we investigated this technique in primary
cancers and metastates of 50 patients with breast cancer,
and compared its value in the detection of recurrent disease
with the serum markers CEA and CA 15-3, which are
commonly used for this purpose.
Patients and methods
We studied 50 patients with 52 primary breast cancers (mean age
61; range, 38-93). After clinical examination and mammography,
cancers were cytologically confirmed to be primary breast cancer.
When patients gave informed consent to this study, blood samples
were taken for measurements of cancer markers and SS-R
scintigraphy was done as an outpatient. After scanning, all patients
had an operation within 14 days, except for one, who had
chemotherapy due to a T4 breast cancer. Preoperative physical
examination and chest X-ray showed no evidence of metastatic
disease, nor were there clinical signs of local spread. 27 patients
were treated by removal of the lump and axillary dissection, 22 with
modified radical mastectomy (2 patients had a bilateral modified
radical mastectomy). The Scarff, Bloom, and Richardson grade
(SBR) was assessed by one pathologist (R v P) in all patients. The
presence of somatostatin receptors in 30 of these cancers was
measured by in-vitro autoradiography (J C R) on cryostat sections
of cancer tissue, as has been described previously. 1,9
The somatostatin analogue [DTPA-D-Phel]-octreotide
(Mallinckrodt Medical BV, Petten, Netherlands) was labelled with
ultra-pure 111Indium.18 Doses ranged from 200 MBq to 272 MBq
["*In-DTPA-D-Phe]-octreotide. Planar images were obtained
with a large field-of-view gamma camera (Counterbalance 3700,
Siemens Gammasonics, Erlangen, Germany) equipped with a
190-KeV parallel-hole collimator. Generally, the field of view
covered the chest and the upper part of the abdomen. 24 hours after
injection of [*"In-DTPA-D-Phe*]-octreotide, chest images were
obtained anteriorly and posteriorly, with additional images of the
axillary region with arms elevated. 500 Kcts were collected per
image with a maximum counting time of 15 min. A simple
high/moderate, low/negative system was used to define the
accumulation of radioactivity by the tumours as seen during
scanning, carried out by E P K and H Y 0, who were not informed
where the cancer was.
Serum samples were stored at - 20&deg;C before assay. Serum CEA
was determined by enzyme-linked immunoassay (ELISA) kits
(Boehringer, Mannheim, Germany) (normal upper limit normal
concentration 10 ng/mL). Serum CA-15 was determined by
ELISA (Centeroor, Leiden, Netherlands).
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Results
39 of the 52 tumours were seen on [In-DTPA-D-Phe]-
octreotide scintigraphy. The intensity of scintigraphy
varied considerably. In figure 1, the S S-R scan is shown of a
70-year-old with bilateral cancer and autoradiographic
results obtained on a section of cancer removed from this
patient, showing specific binding of [1-Tyr] octreotide.
In 30 of these 52 cancers, autoradiographic studies of the
surgically-removed tissue for the presence of S S-R could be
done in parallel to the scintigraphy with [111In-DTPA-D-
Phel]-octreotide. SS-R’s were present in 23 cancers;
comparison between in-vivo scintigraphy and in-vitro
autoradiography showed that receptors were found in both
instances in 22, and absent on both investigatons in 6. A
discrepancy between the in-vivo and in-vitro results was
observed in 2. In one cancer, a non-homogeneously sparse
distribution of SS-R’s was found at autoradiography, while
the tumour was not seen in vivo; in the other, low
radioactivity was seen on the scintigram of the breast
containing a SS-R-negative cancer according to
autoradiography. Two types of SS-R distribution were
recognised at autoradiography: in 16 the receptors were
homogeneously and often densely distributed over the
cancer tissue, while they were found to be non-
homogeneously scattered in 7, all non-invasive ductal
cancers.
Cancers showing a dense distribution of SS-R’s in vitro
were most clearly seen in vivo. Figure 2 shows the scan of a
56-year-old with a T ductal carcinoma with a large
non-invasive component. Autoradiography with
[125I-Tyr3]-octreotide shows only specific binding of
somatostatin throughout the non-invasive component of
the tumour. Figure 3 shows the scintigram of a 39-year-old
patient with a T invasive ductal carcinoma of the left
breast. Physical examination did not reveal palpable lymph
nodes in the axilla. The scan, however, showed
radioactivity in the axilla, and histology confirmed axillary
lymph-node metastases. Of the subsequent 13 consecutive
patients with histologically-proven non-palpable axillary
Figure 1: A: -octreotide scintigraphy showing
bilateral breast cancers. B: Haematoxylin-eosin stained section.
C: Autoradiogram showing total binding of -octreotide.
D: Autoradlogram showing non-specific binding of [llal-Tyr3]-
octreotlde (in presence of 10-6 M Tyr’-octreottde).
Figure 2: A: [111In-DTPA-D-Phe1]-octreotide scintigraphy of a
56-year-old patient showing cancer faintly In the right breast.
B: Haematoxylin-eosin stained sections containing non-invasive
tumour tissue, ductal carclnoma-in-situ (DCIS). C: Autoradio-
gram showing total binding of [125I- Tyr3]-octreotide. Only one
limited region containing DCIS Is strongly labelled. D:
Autoradlogram showing non-specific binding of [125I-Tyr3]-
octreotide (in presence of 10 M Tyr8-octreotlde).
lymph node metastases and a positive SS-R scan of the
primary cancer, lymph-node metastases were seen in 4.
None of the patients with a negative scan of the primary
cancer showed abnormal radioactivity in the axillae or
elsewhere in the body.
There was no correlation between [m_In-DTPA-D-
Phel]-octreotide positivity of the cancers in vivo and age
(<60 yr 15/18 [83%]; >,60 yr 24/34 [71%]). 85% of the
ductal cancers could be seen and 56% of the lobular cancers
(p<0-05). Also, significantly more T cancers were seen
than T1 cancers (p<0-05; table 1). 37 patients with 39
SS-R-positive primary breast cancers were selected to have
repeat SS-R scintigraphy on average 25 yr after initial
treatment (23-36 months). Of these patients, 2 had died
(one due to metastatic breast cancer), 3 were bedridden at
home (2 because of metastatic breast cancer), 2 had been
discharged from follow-up, and 2 refused. Of the remaining
28 with an originally SS-R-positive primary breast cancer,
2 had already had repeat scintigraphy because of suspected
metastases. In one of these, SS-R-positive metastases had
been shown in the liver, lung, and cervical spine; and in the
other, both axillary and mediastinal lymph-node metastases
Figure 3: [111ln-DTPA-D-Phe1]-octreotlde scintigraphy of a
39-year-old patient showing breast cancer on the left side and
axillary-node metastases.
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Table 1: [Uln.DTPA.D.Phe]-octreotlde uptake In primary
breast cancer related to cancer size and stage
were seen on the side of the original breast cancer. 26
patients were symptom-free; physical examination and
scintigraphy showed lesions suspected to be metastases
which were confirmed by biopsy, bone scan, ultrasound, or
computerised tomographic scan: bone (4); liver (1);
pulmonary (2); pleural (1); and in axillary (2),
infraclavicular (1), and mediastinal (1) lymph nodes. In one
patient, treated by cancer removal and axillary dissection, a
local recurrence was seen at SS-R scintigraphy (figure 4).
14 patients with an originally SS-R-positive primary
cancer, had a normal somatostatin scan on follow-up. Slight
scattered radioactivity distributed over one lung was seen in
6 patients after radiotherapy following by cancer removal
and axillary dissection. The 17 with an originally SS-R-
negative scan were not rescanned; none have died and all are
symptom-free.
Serum CA 15-3 and CEA were normal at first
presentation in 35 and 37 patients respectively, with a
SS-R-positive primary cancer and none of these cancer
markers was raised in patients with primary SS-R-negative
tumours, of which the SS-R status is based on SS-R
scintigraphy. At follow-up, only one of the symptomatic
patients had raised CA 15-3 and CEA, and also 1 of the
asymptomatic patients had increased CA 15-3. All patients
Figure 4: A: 58-year-old patient with primary breast cancer of
the left breast. B: 17 months later, mediastinal and axillary
lymphnode metastases were shown on the left side. Treatment
with chemotherapy followed. C: Thirteen months later there was
complete disappearance of the axillary cancer and a pprtial
response of the mediastinal cancer Infiltration
Symptomatic: patients with clinically-overt metastatic disease.
Asymptomatic: patients without clinically-overt metastatic disease.
Table 2: CA 15-3 and CEA In patients with SS-R-positive primary
breast cancers and proven recurrent disease according to SS-R
scintigraphy at follow up of 30 months
with a normal SS-R scan at follow-up had serum cancer-
marker values in the normal range except for 1 who had a
slightly elevated CA 15-3 as was the case at first
presentation (table 2).
Discussion
SS-R imaging has been shown to be successful in the
identification of primary as well as metastatic cancer sites of
a variety of neuroendocrine tumours.12-16 Validation of the
technique was by in-vitro demonstration of high-affinity
binding sites for somatostatin in those cancers, which had
been shown in vivo.14 A positive SS-R scan closely
predicted a beneficial effect of octreotide treatment on
hormonal hypersecretion by these tumours.
Some breast cancers contain SS-Rs measured in vitro. In
a group of 158 small breast-cancer samples (mean section
surface 14 mm2) 34 (21 %) were SS-R positive, while in a
group of 72 larger cancer samples (mean section surface 180
mm2) 33 tumours (46%) were SS-R positive.6 A
subpopulation of SS-R-positive breast cancers is probably
of neuroendocrine origin.8.17 The percentage of SS-R-
positive cases varies not only with the specificity and
sensitivity of the neuroendocrine markers used, but
depended also on the number of tissue slices per cancer
investigated microscopically. We showed 39 of 52 primary
breast cancers (75%) to be somatostatin-receptor positive
by scintigraphy. There was a close correlation between the
in vivo 
-octreotide scan and
subsequent in vitro autoradiography with 123I-Tyr3-
octreotide. There was variability in radioactivity at SS-R
scintigraphy; higher density in vivo correlated mostly with
homogeneous and dense distribution of SS-Rs at
autoradiography, while lower density of radioactivity over
the cancer area in vivo corresponded with a non-
homogeneous and sparse distribution of these receptors in
vitro. Interestingly, low density of receptors seemed to be
due to a non-invasive cancer component, mainly ductal
carcinoma-in-situ.
The high incidence of SS-Rs in these 52 cancers, as
observed by scintigraphy might be due to several causes.
Firstly, in-vivo SS-R demonstration of breast cancer may
be more sensitive than in-vitro autoradiography, as
scintigraphy shows the presence of receptors in the whole
cancer. In accordance with this, statistically significantly
more T2 than T1 cancers were seen in vivo. Secondly, our
patients might represent a selected group in comparison
with those from other countries, as the incidence of ductal
cancers amongst patients with newly-diagnosed breast
cancers has increased over the last years in the Netherlands
following the introduction of routine and repeated
screening of the population.19 Little is known about the
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biological behaviour of SS-R-positive breast cancer,
although a retrospective study of 110 patients20 suggested
that the presence of SS-R might predict a longer disease-
free survival. Also, in-vitro studies of more than 300
breast-cancer samples showed an inverse relationship
between somatostatin and EGF-receptor expression.6,9
These observations suggest that patients with SS-R-
positive cancers might have a relatively good prognosis.
This, however, is not substantiated by our observations.
After a mean follow-up of 2-5 yr we found that of 37 SS-R-
positive patients 5 had extensive metastases, and also 6 of 26
symptom-free patients had metastases initially shown by
SS-R-receptor scintigraphy.
CA 15-3 and CEA are the most commonly-used cancer
markers to monitor patients with recurrent breast cancer.
Both were raised in only 5-20% of women with primary
breast cancer, but elevations between 61 % and 84 % have
been recorded for women with extensive metastatic disease.
CA 15-3 seems to be related to the extent of the metastases,
the number of metastatic sites and survival, whereas CEA is
only correlated with the extent of disease.21.22 We show a
higher sensitivity of SS-R scintigraphy compared with
these cancer markers in detecting the development of
recurrence in patients with SS-R-positive primary breast
cancer. SS-R scintigraphy showed recurrent disseminated
breast cancer in 6 (only 1 of whom had symptoms of
recurrence) out of 28 patients with SS-R-positive primary
cancers; all 6 patients had normal CA 15-3 and CEA.
Another 3 out of these 28 patients had abnormal serum
cancer markers, 2 of whom had an abnormal SS-R
scintigram. The 3rd patient, who only showed marginally
elevated CA 15-3 both at first presentation and follow-up, is
clinically in remission 3-2 yr after the operation. Peptide-
receptor demonstration of primary breast cancer with a
radionuclide-labelled somatostatin analogue is successful
in 75% of cases.
At primary diagnosis, the scintigraphic technique seems
of minor value in the detection of axillary lymph node
metastases; detection of these may be improved with guided
surgery using a hand-held radio-nuclide detecting probe
after administration of a radionuclide-labelled somatostatin
analogue. The results so far also suggest that distant
metastases of the primary somatostatin-receptor breast
cancers continue to express such receptors at a mean of 2 5
yr after initial treatment. Scintigraphy showed the
unexpected presence of metastases in nearly 25% of
symptom-free initially SS-R-positive breast cancer
patients, who had normal CA 15-3 and CEA serum values.
The clinical relevance of detecting recurrent disease in an
early stage is not known.
In-vitro studies with breast-cancer cell lines indicate a
direct receptor-mediated inhibitory effect of somatostatin
analogues on cell proliferation.1O,23-2s No prospective,
controlled studies on the use of somatostatin analogue in
patients with breast cancer have yet been published. As
SS-R scintigraphy is effective in the early detection of
SS-R-positive breast cancer recurrence, it may have future
use in the selection of patients who can be treated with
somatostatin analogues or radiotherapy with an a-emitting
or p-emitting radionuclide coupled to a somatostatin
analogue.
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